BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/1/2026 4:34:34 AM | Browse: 0 | Download: 0
 |
Received |
|
2026-02-27 03:17 |
|
Peer-Review Started |
|
2026-02-27 03:17 |
|
First Decision by Editorial Office Director |
|
2026-04-15 08:59 |
|
Return for Revision |
|
2026-04-15 08:59 |
|
Revised |
|
2026-04-30 08:46 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2026-05-22 02:37 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2026-05-22 06:07 |
|
Articles in Press |
|
2026-05-22 06:07 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2026-08-24 08:35 |
|
Publish the Manuscript Online |
|
2026-09-01 04:34 |
| ISSN |
2150-5349 (online) |
| Open Access |
This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc. |
| Copyright |
©Author(s) (or their employer(s)) 2026. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Systematic Reviews |
| Article Title |
Survival in unresectable hepatocellular carcinoma: Comparison of four treatments based on patients reconstructed from Kaplan–Meier curves of randomized trials
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Vera Damuzzo, Stefano Vecchia, Lorenzo Gasperoni, Luna Del Bono, Andrea Ossato, Elena Orlandi and Andrea Messori |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Andrea Messori, Osservatorio Innovazione Section, HTA Regione Toscana, via Alderotti 26/N, Firenze 50139, Italia, Italy. andrea.messori@osservatorioinnovazione.net |
| Key Words |
Hepatocellular carcinoma; Immune checkpoint inhibitors; Tyrosine kinase inhibitors; Indirect comparison; Overall survival |
| Core Tip |
In the absence of head-to-head trials for first-line unresectable hepatocellular carcinoma, we reconstructed individual patient data from eight phase III trials to indirectly compare immune checkpoint inhibitor and tyrosine kinase inhibitor combinations. Most regimens outperformed sorafenib, with camrelizumab plus rivoceranib emerging as the most effective option, demonstrating superiority over tremelimumab plus durvalumab and anlotinib plus penpulimab. Restricted mean survival time analyses revealed revealed that nivolumab plus ipilimumab, lenvatinib, and pembrolizumab plus lenvatinib achieved results similar to those of camrelizumab plus rivoceranib. These findings provide a practical framework for treatment positioning and underscore the critical influence of comparator on estimated efficacy. |
| Publish Date |
2026-09-01 04:34 |
| Citation |
Damuzzo V, Vecchia S, Gasperoni L, Del Bono L, Ossato A, Orlandi E, Messori A. Survival in unresectable hepatocellular carcinoma: Comparison of four treatments based on patients reconstructed from Kaplan–Meier curves of randomized trials. World J Gastrointest Pharmacol Ther 2026; 17(3): 120377
|
| URL |
https://www.wjgnet.com/2150-5349/full/v17/i3/120377.htm |
| DOI |
https://doi.org/10.4292/wjgpt.120377 |
Copyright © 1993-2026 Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA. All rights reserved, including rights relating to text and data mining, AI training, and similar technologies. For open-access content, the applicable copyright and licensing terms govern.
